pmc logo imageJournal ListSearchpmc logo image
Logo of nihpaNIHPA bannerabout author manuscriptssubmit a manuscript
J Inorg Biochem.Author manuscript; available in PMC 2008 February 11.
Published in final edited form as:
Published online 2007 August 10. doi: 10.1016/j.jinorgbio.2007.07.039.
PMCID: PMC2238680
NIHMSID: NIHMS37382
Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators
Matt L. Childers,a Joonhyung Cho,a Celeste A. S. Regino,b Martin W. Brechbiel,b Antonio G. DiPasquale,c Arnold L. Rheingold,c Suzy V. Torti,d Frank M. Torti,d and Roy P. Planalpa1
a Department of Chemistry, University of New Hampshire, Durham, NH 03824-3598
b Radiation Oncology Branch, National Institutes of Health, Bethesda, MD 20892
c Department of Chemistry, University of California, San Diego, CA 92093
d Departments of Biochemistry and Cancer Biology and the Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157
1 corresponding author. E-mail: Roy.planalp/at/unh.edu
Abstract
The Fe coordination chemistry of several tripodal aminopyridyl hexadentate chelators is reported along with cytotoxicity toward cultured Hela cells. The chelators are based on cis, cis-1,3,5-triaminocyclohexane (tach) with three pendant –CH2–2-pyridyl groups where 2-pyridyl is R-substituted thus are named tach-x-Rpyr where x=3, R=Me; x=3, R=MeO; x=6; R=Me. The structures of [Fe(tach-3-Mepyr)]Cl2 and [Fe(tach-3-MeOpyr)](FeCl4) are reported and their metric parameters indicate strongly-bound, low-spin Fe(II). The structure of [Fe(tach-6-Mepyr)](ClO4)2 implies steric effects of 6–Me groups push donor Npy’s away so one Fe-Npy bond is substantially longer at 2.380(3) Å vs. 2.228(3) Å for the others, and Fe(II) in the high-spin state. Accordingly, anions X = Cl or SCN afford [Fe(tach-6-Mepyr)(X)]+ from [Fe(tach-6-Mepyr)]2+ (UV-vis spectroscopy). Consistent with a biological cytotoxicity involving Fe chelation, chelators of low-spin Fe(II) have greater toxicity in the order [IC50(72 h) is in parentheses then the spin-state SS=H (high) or L (low)]: tachpyr = tach-3-Mepyr (6 μM, SS=L) [greater, similar]tach-3-MeOpyr (12 μM, SS=L) [dbl greater-than sign] tach-6-Mepyr (> 200 μM, SS=H). Iron-mediated oxidative dehydrogenation with O2 oxidant removes hydrogens from coordinated nitrogen and the adjacent CH2, converting aqueous [Fe(tach-3-Rpyr)]2+ (R = H, Me and MeO) into a mix of low-spin imino– and aminopyridyl-armed complexes, but [Fe(tach-6-Mepyr)]2+ does not react (NMR and ESI-MS spectroscopies). The difference of IC50 for chelators at different time points (ΔIC50 = [IC50(24 h) − IC50(72 h)]) is used to compare rate of cytotoxic action to qualitative rate of oxidation in the Fe-bound chelator, giving the order: [Fe(tach-3-Mepyr)]2+ (ΔIC50 = 5 μM) > [Fe(tachpyr)]2+ (ΔIC50 = 16 μM) > [Fe(tach-3-MeOpyr)]2+ (ΔIC50 = 118 μM). Thus, those chelators whose Fe(II) complexes undergo rapid oxidation kill cells faster, and those that bind Fe(II) as low-spin are far more cytotoxic.
Keywords: redox reaction, antitumor agent, ligand design, tripodal chelator, Fe(II)
Introduction

Many studies now show that the cis, cis-1,3,5-triaminocyclohexane (tach) framework is well-suited to complexation of first-row dicationic transition-metals of ionic radius[1] 0.75 to 0.88 Å.[24] In studies of aqueous and biological coordination chemistry, we identified the N, N, N″-2-pyridylmethyl pendant arm derivative, tachpyr, as a Zn(II)- and Fe(II)-complexing agent in vitro as well as a cytotoxic agent with potential application to cancer therapy.[57] Notably upon treatment of cells with tachpyr, ferritin synthesis is depressed, which is indicative of cellular iron deficiency.[6] In addition to a cytotoxic pathway involving sequestration and cellular deprivation of biometal ions by chelators, the induction of cellular oxidative damage via catalytic coordinated metal ion is also possible.[8] The cytotoxicity of tripodal aminopyridyl chelators based on tach and tren (tris(2-aminoethyl)amine) frameworks is quite sensitive to substituents on both the pyridyl rings and the framework amine nitrogens. Specifically, methylation at the pyridine-ring 6-position or the amine nitrogen completely suppresses aqueous metal ion-chelation and cytotoxicity, while methylation at the 3-ring position does not hinder metal chelation and accelerates cell death.[911]

When certain tachpyr-family chelators bind Fe(II) under aerobic conditions (or bind Fe(III) under N2 or O2, or when Fe(II)-tach-family complexes are exposed to oxidants), iron-mediated oxidative dehydrogenation occurs giving [Fe(tachpyr-monoimine)]2+ and [Fe(tachpyr-diimine)]2+ complexes, as shown in Scheme 1. For reasons that will be discussed in a separate paper, tachpyr-trisimine does not interact strongly with Fe(II) and the [Fe(tachpyr-trisimine)]2+ complexes do not form readily. This reaction is significant to chemistry and biology of these chelators in at least two ways. The redox process may generate reactive oxygen species that can cause cellular injury and death.[12] Second, π-backbonding is greater to the iminopyridyl group than to the aminopyridyl group, affording stronger Fe(II) binding.[13] Thus although Zn(II) competes favorably with Fe(II) for tachpyr under anaerobic conditions, under aerobic conditions tachpyr binds increasing amounts of iron relative to zinc, which we postulated is due to inertness of Fe(II)-tachpyr-mono- and bis-imine complexes relative to the reversibly-bound Zn(II) of the complex [Zn(tachpyr)]2+.[14] Studies of extracts of cells treated with tachpyr indicate that the mono- and bis-imine complexes are likely forms of sequestered iron or zinc in cells.[5]

Scheme 1Scheme 1
Fe(II) complexes studied herein.

It was therefore of great interest to pursue further substitutions (beyond methylation) at the 3-position of the tachpyr chelator, particularly to study oxidative dehydrogenation of Fe complexes with derivatized tachpyr. Herein, we report synthesis of the 3-methoxylated chelator, tach-3-MeOpyr, structural and solution properties of the Fe(II) complexes of tach-3-Mepyr, tach-3-MeOpyr and tach-6-Mepyr, the oxidative dehydrogenation reactivity of the Fe(II)-complexes of these three chelators relative to the parent tachpyr, and a comparison of cytotoxic action of the chelators toward cultured Hela cells.

Synthesis and spectra

The chelator1 tach-3-MeOpyr was synthesized from the triamine and the appropriately substituted pyridine carboxaldehyde by first forming a tris-imine that was subsequently reduced to tris-amine. The ligand readily complexed Fe(II) as seen by reaction with a slight excess of FeCl2•4H2O in MeOH or H2O under anaerobic conditions. The complex crystallized as [Fe(tach-3-MeOpyr)](FeCl4)•2MeOH2 when a greater excess of FeCl2•4H2O was employed. We prepared the ligands tach-3-Mepyr, tach-6-Mepyr and tachpyr plus their Fe(II) complexes 1, 3, and 4 as previously reported (Scheme 1).[9,15]

The 1H NMR spectrum of [Fe(tach-3MeOpyr] 2+ indicates a diamagnetic, low-spin state of Fe(II), while the electronic spectrum is dominated by a metal-to-ligand charge-transfer (MLCT) band at 23000 cm−1 (ε= 6500 M−1 cm−1) with a low-energy shoulder at 18800 cm−1 (ε = 350 M−1 cm−1), quite similar to that of [Fe(tach-3-Mepyr)]2+ whose MLCT band appears at 22700 cm−1 (ε = 7000 M−1 cm−1) and shoulder at 18200 cm−1 (ε = 290 M−1 cm−1).[9] The low-energy shoulder has previously been assigned as the 1A1g1T1g transition.[16,17]

Iron-mediated oxidative dehydrogenation

In order to investigate the process of oxidative dehydrogenation in the ring-substituted tach chelators, solutions of [Fe(tach-3-Mepyr)]2+ (1) or [Fe(tach-3-MeOpyr)]2+ (2) were exposed to air. This caused iron mediated oxidative dehydrogenation, with spectral changes matching those we reported for a solution of [Fe(tachpyr)]2+ (4).[11] For both 1 and 2, a new charge-transfer band having a high-energy shoulder appears at ca. 16250 cm−1 and as the oxidation progresses, the MLCT band at ca. 23000 cm−1 shifts toward higher energy while the band at ca. 16250 cm−1 gains intensity as the solution changes from amber to green and ultimately blue, consistent with conversion to a mixture of two [Fe(tach-3-Rpyr-imino)]2+ species (Scheme 1). Because the monoimine complexes (left structure of Scheme 1) are oxidized by 2 H•, they are designated [Fe(tach-3-Rpyr-ox-2)]2+ and similarly the bisimine complexes (right structure of Scheme 1) are termed [Fe(tach-3-Rpyr-ox-4)]2+ (R = Me or MeO). As expected from the low-spin, diamagnetic NMR and in analogy to other chelated σ-donor, π-acceptor ligand Fe(II) complexes such as [Fe(phen)3]2+, the tach-3-Mepyr and tach-3-MeOpyr ligands and their mono- and diimino derivatives interact strongly with Fe(II). Oxidative dehydrogenation reactivity is not observed for the high-spin complex [Fe(tach-6-Mepyr)]2+.

Comparisons of the rates of oxidative-dehydrogenation between 1, 2 and 4 were obtained using 1H NMR and ESI-MS. Proton NMR proved useful for quantitation using the signals of the imino protons, –N=CH–, which appear as a singlet in the range of 9.2 to 9.6 ppm for the monoimino complexes derived from 1, 2 and 4 and as a doublet in the range of 8.8 to 9.2 ppm for the diimino complexes. Figure 1 shows the 1H NMR of 1 in the useful region for quantitation of the amount of monoimine formed, where the aromatic protons are arbitrarily set to 100 H and the integral of the monoimine species at δ 9.59 is measured at 4 h and 24 h exposure to air. Similar data was obtained for 2 and 4 and all integrals are tabulated in Table 1. This data was supported by electrospray-mass spectroscopic studies of the oxidized mixtures, which are shown in the Supplementary Data along with the 1H NMR spectra of 2 and 4. The qualitative order of oxidation rate of the tach-3-Rpyr family is tach-3-Mepyr > tachpyr > tach-3-MeOpyr (Table 1). Due to the similar chemical properties of the oxidized species, they could not be separated, and a rigorous kinetic analysis of the oxidation process was not successful, which was attributed to the overlap of spectral peaks from the concurrent conversions of [FeL]2+ → [Fe(L-ox-2)]2+ and [Fe(L-ox-2)]2+ → [Fe(L-ox-4)]2+, precluding accurate quantitation of reactants and products.

Figure 1Figure 1
Proton NMR spectrum (D2O, 25 °C) of the progressing oxidation of [Fe(tach-3-Mepyr)]2+ (24 h, upper; 4 h, lower) showing the monoimine species as a singlet at δ 9.56 ppm and diimine as a doublet centered at δ 9.25 ppm. The integration (more ...)
Table 1Table 1
Ratio of the area under the monoimine peak of [Fe(L-ox-2)]2+ to the area under the aromatic peaks (1H NMR, D2O, 25 °C).

At present, an explanation for the above rate order is not apparent. Goto et. al. reported an effect of geometry upon oxidative dehydrogenation, whereby the mer- isomer of [FeII(ampy)2(CN)3] formed an Fe(II)-imine complex when oxidized with peroxodisulfate, but oxidation of the fac- isomer produced fac-[FeIII(ampy)2(CN)3]. However in the present case, there is no significant difference in coordination geometry of 1 vs. 2, nor is there any substantial difference in ligand-field strength of the three ligands 1, 2 and 4, based on interpretation of the electronic spectra of the Ni(II) and Cu(II) complexes.[9][18] Although numerous examples of iron-mediated oxidative dehydrogenation are known, more study of the mechanistic aspects is needed.[1922] By comparison greater progress has been made understanding the oxidative dehydrogenation of Ru and Os complexes, possibly because the reaction mediated by these metals is slower and easier to study.[13,2327].

Ligand substitution

Although the chelator tach-6-Mepyr has been found not cytotoxic,[9] the possibility that its iron complex possesses an open coordination site was studied. It is known that open coordination sites in iron complexes are important to the redox activity of complexes such as [Fe(II/III)EDTA]2−/−.[28] The complex [Fe(tach-6-Mepyr)]2+ has been assigned as high-spin (HS) based on an MLCT band at 28800 cm−1 (ε of this band is weak, 650 M−1 cm−1, as is characteristic of Fe(II)-HS) along with a weak d-d transition at 11700 cm−1 (ε= 9.4 M−1 cm−1) in the UV-Vis spectrum and a measured magnetic moment μeff = 5.46 B.M. (DMSO solution, Evans’ method).[9] In view of this and the X-ray structural findings (vide infra), it was considered likely that 3 could contain an open or substitutable coordination site in solution. Therefore, ancillary ligands were added to a MeCN solution of 3 to probe the presence of such sites. With the addition of one molar equivalent of either a chloride or thiocyanate anion, a red shift of the charge-transfer band was observed. The shift is believed to be due to the formation of [Fe(tach-6-Mepyr)(Cl)]+ and [Fe(tach-6-Mepyr)(SCN)]+ respectively, as this is consistent with observations of Bernal and Toftlund who identified replacement of pyridine by water in another FeII complex of a ligand containing 6-methyl-2-aminomethylpyridyl donors, [Fe(N,N′-bis(6-methyl-2-pyridylmethyl)-N,N′-bis(2-pyridylmethyl)ethane-1,2-diamine)(H2O)]2+.[29] In sum, although this experiment could not be conducted in aqueous medium due to the lability of [Fe(tach-6-Mepyr)]2+,[9], the reactivity of 3 in MeCN solvent is predicted by its structure.

Structural studies

To obtain further chelator structural parameters that may underlie optimal Fe(II) binding, the X-ray structures3 of the dications 1, 2 and 3 were determined as the salts [Fe(tach-3-Mepyr)]Cl2•2MeOH, [Fe(tach-3-MeOpyr)](FeCl4)•2MeOH, and [Fe(tach-6-Mepyr)](ClO4)2•H2O•MeOH respectively (Figures 24). The average Fe-Npy and Fe-Namine bond lengths for 1 and 2 are shown in Table 2. A comparison with other low-spin (LS), six-coordinate Fe(II) complexes that contain the 2-aminomethylpyridyl group such as [Fe(tptcn)]2+ and fac-[Fe(ampy)3]2+ shows good agreement in the bond lengths (Table 1). As expected, the Fe-Npy bonds are generally shorter than Fe-Namine bonds due to dπ → pπ* backbonding of Fe(II) to the ligand.[30] Both 1 and 2 possess a trigonally distorted octahedral coordination geometry, as indicated by their trigonal twist angles ([var phi]) of 54.9° and 54.6° respectively compared to a [var phi] of 60° for a perfect octahedron. The average Npy–Fe–Namine angles of the 5-membered chelate rings (α) of 83.6° in 1 and 84.0° in 2 are comparable to other LS aminomethylpyridyl iron complexes as seen in the top section of Table 2.

Figure 2Figure 2
Structure of the complex cation of [Fe(tach-3-Mepyr)]Cl2 (ORTEP; 50% probability ellipsoids) showing the atom-numbering scheme.
Figure 4Figure 4
Structure of the complex cation of [Fe(tach-6-Mepyr)](ClO4)2 (ORTEP; 50% probability ellipsoids) showing the atom-numbering scheme.
Table 2Table 2
Selected structural parameters of [Fe(tach-3-Mepyr)]2+ (1), [Fe(tach-3-MeOpyr)]2+ (2), [Fe(tach-6-Mepyr)]2+ (3), and reference compounds.

The average Fe-Npy and Fe-Namine bond lengths for 3 are 2.279(3) and 2.173(3) Å respectively. The elongation of the Fe-N bonds in 3 compared to 1 and 2 is attributed to the HS nature of the complex where electrons now populate the eg* orbitals and the six-coordinate ionic radius of Fe(II) is 0.92 Å. The steric interactions between the 6-methyl groups are most evident when examining the Fe-Npy bonds. For each of the two independent molecules in the asymmetric unit there is one Fe-Npy bond that is ~0.15 Å longer than the other two. The lengthening of one bond to compensate for steric interactions between 6-methyl groups was also reported in the Zn(II) and Mn(II) complexes of the same ligand, which are isostructural with [Fe(tach-6-Mepyr)](ClO4)2 (Table 1, bottom section).[9] Even with these steric interactions the complex is able to obtain a geometry close to octahedral with an average twist angle of 53.0°. The bite angle of 77.9° is consistent with the elongated Fe-N bonds and is in good agreement with other HS aminopyridyl iron complexes as seen in Table 2. Taken together the structural findings indicate that tach-3-Mepyr and tach-3-MeOpyr interact strongly with Fe(II) in an ideal geometry for this metal ion, whereas steric hindrance prevents a good interaction of tach-6-Mepyr with Fe(II).

Cytotoxicity

The cytotoxicities of tach-3-Mepyr and tach-3-MeOpyr toward cultured Hela cancer cells4 were determined against a tachpyr control (Table 3). The chelator tach-6-Mepyr displayed no cytotoxicity and was not studied further. At 24 h tach-3-Mepyr is more toxic than tachpyr and much more toxic than tach-3-MeOpyr. However, the toxicity of tach-3-MeOpyr increases dramatically from 24 h to 72 h, as expressed by the value ΔIC50 (24h – 72h). After 72 h, it only takes twice as much tach-3-MeOpyr as either tach-3-Mepyr or tachpyr to kill half the cells. This finding might be explained by the need for a greater degree of imine formation in order to retain bound iron. Thus, a chelator with slower iron-mediated oxidative dehydrogenation such as tach-3-MeOpyr does not convert to the inert [Fe(L-monoimine)]2+ form as quickly, so it takes longer to sequester iron inertly. An alternative explanation which cannot be distinguished at this time is that the oxidative dehydrogenation activity forms reactive oxygen species which cause cell death. It is also possible that tach-3-MeOpyr does not as readily diffuse to the regions of the cell where iron may be bound.

Table 3Table 3
IC50 values (μM) of tachpyr, tach-3-Mepyr, and tach-3-MeOpyr after 24, 48, and 72 h.
Conclusions

The chelators tach-3-Mepyr, tach-3-MeOpyr and tachpyr bind Fe(II) strongly and equally well based on ground-state structure, however their rates of iron-mediated oxidative dehydrogenation differ in the order, fast to slow, of tach-3-Mepyr > tachpyr > tach-3-MeOpyr. They are equally cytotoxic to cultured Hela cells, but their rates of cell-killing are also in the order fast to slow of tach-3-Mepyr > tachpyr > tach-3-MeOpyr. The underlying biological and chemical reasons for these relationships are not yet understood. Introduction of steric bulk produces an elongated Fe(II)-Npy bond in the structure of [Fe(tach-6-Mepyr)]2+ and accordingly this complex has a substitutable coordination site in MeCN solution.

Figure 3Figure 3
Structure of the complex cation of [Fe(tach-3-MeOpyr)](FeCl4) (ORTEP; 50% probability ellipsoids) showing the atom-numbering scheme.
Scheme 2Scheme 2
Chelators for structural comparisons to 1, 2, and 3.
Supplementary Material
01

Fig. S1. 1H NMR spectra of the oxidation of [Fe(tach-3-MeOpyr)]2+ by air to [Fe(tach-3-MeOpyr-ox-n)]2+ (n=2, 4) (D2O, 25 °C).

02

Fig. S2. 1H NMR spectra of the oxidation of [Fe(tachpyr)]2+ by air to [Fe(tachpyr-ox-n)]2+ (n=2, 4) (D2O, 25 °C).

03

Fig. S3. ESI-MS spectrum of [Fe(tach-3-Mepyr)]2+ showing as base peak the ion {[Fe(tach-3-Mepyr)]–H+}+ and simulation in the inset.

04

Fig. S4. ESI-MS spectrum (m/2) of partially-oxidized [Fe(tach-3-Mepyr)]2+ showing the complexes {[Fe(tach-3-Mepyr)]–CH3}2+ (242.1), [Fe(tach-3-Mepyr-ox-2)]2+ (249.2), and [Fe(tach-3-Mepyr)]2+ (250.1).

05

Fig. S5. ESI-MS spectrum of oxidized [Fe(tach-3-MeOpyr)]2+ showing as base peak the ion {[Fe(tach-3-MeOpyr-ox-4)]–H+}+.

Acknowledgments

We thank the NIH for the support of this work through Grant DK-57781-R01 to S. V. T. and through the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Appendix A. Supplementary data

The 1H NMR spectra of the oxidation process of 2 and 4 and ESI-MS spectra of 1 and 2 are contained in the supplementary data, which can be found in the online version, at _____. The CIF files for the structural analyses of [Fe(tach-3-Mepyr)]Cl2•2MeOH, [Fe(tach-3-MeOpyr)](FeCl4)•Et2O and [Fe(tach-6-Mepyr)](ClO4)2•H2O•MeOH havebeen deposited with the Cambridge Crystallographic Data Centre, CCDC nos. 621772, 620255, and 620253. Copies of this information may be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or from The Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax: +44-1233-336033; e-mail deposit/at/ccdc.cam.ac.uk).

Footnotes
1tach-3-MeOpyr. N,N,N-tris(3-methoxy-2-pyridylmethyl)-1,3,5-cis,cis-triaminocyclohexane. Tach(HBr)3 (0.58 g, 2.43 mmol) was dissolved in H2O (10 mL) with NaOH (0.292 g, 7.32 mmol) to form a clear solution. Benzene (120 mL) was added and the water was removed by azeotropic distillation with a Dean-Stark trap. 3-Methoxy-pyridine-2-carboxaldehyde (FMC Lithium) (1.00 g, 7.30 mmol) was added in benzene (10 mL) during this process and continued for 12 h. After cooling, the solution was decanted and rotary evaporated to a solid. 13C NMR (CDCl3) δ 156.0, 155.3, 142.9, 142.5, 128.5, 125.7, 119.0, 67.2, 55.7, 40.7; Mass. Spect. Calcd. for C27H31N6O3 487.2458; Found 487.2468. The tris-imine (1.18 g, 2.42 mmol) was dissolved in MeOH (125 mL) and directly reduced with sodium borohydride (0.28 g, 7.3 mmol). After stirring for 18 hr, the reaction solvent was removed by rotary evaporation. The residue was taken up in CHCl3 (100 mL) and vigorously stirred with a 1:1 mixture of sat. NaCl solution and 5% NaHCO3 solution for 1 h. Afterwards, the organic phase was separated, dried over Na2SO4, filtered and solvent removed by rotary evaporation to provide the final product as a dark oil (0.97 g, 81 %). 1H NMR (DMSO-d6, s, singlet; d, doublet; dd, doublet of doublets; q, quartet; br s, broad singlet; br d, broad doublet; br t, broad triplet) δ 8.11 (dd, 1H, J = 4.65, 1.5), 7.53 (dd, 1H, J = 8.55, 1.5), 7.45 (dd, 1H, J = 8.55, 4.8), 4.23 (s, 2H), 3.92 (s, 3H), 3.07 (br. t, 1H), 2.51 (br. d, 1H, J = 11.4), 1.44 (q, 1H, J = 11.7), 13C NMR (d6-DMSO) δ153.5, 149.1, 140.6, 122.7, 116.9, 55.4, 54.2, 47.0, 40.0; Mass Spect. Calcd. for C27H37N6O3 493.2927; Found 493.2925.
2[Fe(tach-3-MeOpyr)](FeCl4)2MeOH A pale green solution of FeCl2•4H2O (0.0101 g, 5.10×10−5 mol) in MeOH (1 mL) was added to a pale yellow solution of tach-3-MeOpyr (0.0174 g, 3.53×10−5 mol) in MeOH (1 mL) producing a brown-red solution. Diffusion of Et2O into the solution overnight gave clusters of red plates. The precipitate was recystalized with MeOH (0.75 mL) and MeCN (0.75 mL) by Et2O diffusion overnight, producing clusters of carmine red plates suitable for X-ray crystallography. Product was isolated and dried under reduced pressure affording deep red plates. 1H NMR (400 MHz, (CD3)2SO, 25 °C) of a sample of [Fe(tach-3-Mepyr)]Cl2 prepared similarly from 6.90 × 10−3 g FeCl2•4H2O (3.47 × 10−5 mol) and 0.0161 g tach-3-MeOpyr (3.27 × 10−5 mol): δ 7.47, 7.23, 6.65 (d, dd, d, 3H, 3-Me-C5H3N); 5.28 (br t, 1H, NH-CH2); 4.23, 3.96 (dd, dd, 2H, (NH-CH2-py), diastereotopic); 3.88 (s, 3H, (CH3O-py)); 2.96 (br s, 1H, cyclohexyl methine H); 2.00 (br d, 1H, equatorial cyclohexyl methylene H); 1.85 (br d, 1H, axial cyclohexyl methylene H). Anal. Calcd for C29H44Cl4Fe2N6O5 (810.20): C, 42.99; H, 5.47; N, 10.37. Found: C, 42.91; H, 5.50; N, 10.26.
3Crystal data. Suitable crystals of [Fe(tach-3-Mepyr)]Cl2•2MeOH were grown from a MeOH/MeCN (1:1 v/v)solution of Fe(tach-3-Mepyr)]Cl2, those of [Fe(tach-3-MeOpyr)](FeCl4)•2MeOH from a MeOH/MeCN solution by vapor-phase diffusion of Et2O and those of [Fe(tach-6-Mepyr)](ClO4)2•H2O•MeOH from MeOH at 5°C. Crystal data for [Fe(tach-3-Mepyr)]Cl22MeOH (Figure 2): Dark red fragments, crystal dimensions 0.20 × 0.25 × 0.25 mm, C29.50H46Cl2FeN6O2.50, M = 651.47, monoclinic, space group P21/n, a = 10.9853(7), b = 13.5083(8), c = 21.1005(13) Å, β = 91.1240(10)°, V = 3130.5(3) Å, Z = 4, Dc = 1.382 g cm3, μ(Mo Kα) = 0.692 mm−1. A total of 19145 reflections were used, 1.79° < θ < 28.19°. A total of 7043 independent reflections having I > 2σ(I); 337 parameters. Final results: R(F) = 0.0368, Rw(F) = 0.0970, GOF = 1.101, maximum residual electronic density = 0.661 eÅ−3. Crystal data for [Fe(tach-3-MeOpyr)](FeCl4)Et2O (Figure 3): Brown fragments, crystal dimensions 0.15 × 0.15 × 0.03 mm, C31H46Cl4Fe2N6O4, M = 820.24, orthorhombic, space group P212121, a = 12.3590(9), b = 14.2250(11), c = 20.4170(15) Å, α= β = γ = 90°, V = 3589.4(5) Å, Z = 4, Dc = 1.518 g cm3, μ(Mo Kα) = 1.151 mm−1. A total of 8113 reflections were used, 2.18° < θ < 28.19°. A total of 8113 independent reflections having I > 2σ(I); 382 parameters. Final results: R(F) = 0.0413, Rw(F) = 0.0746, GOF = 0.959, maximum residual electronic density = 0.569 eÅ−3. Crystal data for [Fe(tach-6-Mepyr)](ClO4)2H2OMeOH (Figure 4). Dichroic/red plates, crystal dimensions 0.40 × 0.30 × 0.08 mm, C55H75Cl4Fe2N12O18, M = 1445.77, triclinic, space group P-1, a = 9.5245(9), b = 17.4908(17), c = 19.0395(19) Å, α = 96.239(2)°, β = 95.334(2)°, γ = 95.093(2)°, V = 3123.7(5) Å, Z = 4, Dc = 1.924 g cm3, μ(Mo Kα) = 1.383 mm−1. A total of 20964 reflections were used, 1.69° < θ < 26.00°. A total of 12159 independent reflections having I > 2σ(I); 821 parameters. Final results: R(F) = 0.0607, Rw(F) = 0.1648, GOF = 1.202, maximum residual electronic density = 1.051 eÅ−3.
4HeLa cells were obtained from the American Type Culture Collection and grown in a humidified 5% CO2 atmosphere at 37°C in Dulbecco’s modified Eagle’s medium (Gibco BRL) supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells (2 × 103) were plated in 96 well tissue culture dishes and allowed to attach overnight before test compounds were added at various concentrations. Six replicate cultures were used for each point. After 72 h, viability was assessed using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, in which MTT is added to the medium and the formation of a reduced product is assayed by measuring the optical density at 560/650 nm after 3 hours. Color formation is proportional to viable cell number[34] T. Mosmann, J. Immunol. Methods 65 (1983) 55–63.. IC50 is the concentration of chelator required to inhibit proliferation by 50%.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
1.
Shannon, R. Acta Crystallogr, Sect A. 1976;A32:751–767.
2.
Ghisletta, M; Jalett, HP; Gerfin, T; Gramlich, V; Hegetschweiler, K. Helv Chim Acta. 1992;75:2233.
3.
Hegetschweiler, K. Chem Soc Rev. 1999;28:239–249.
4.
Park, G; Przyborowska, AM; Ye, N; Tsoupas, N; Bauer, CB; Broker, GA; Rogers, RD; Brechbiel, MW; Planalp, RP. J Chem Soc, Dalton Trans. 2003:318–324.
5.
Zhao, R; Planalp, RP; Ma, R; Greene, B; Jones, B; Brechbiel, M; Torti, FM; Torti, SV. Biochem Pharmacol. 2004;67:1677–1688. [PubMed]
6.
Torti, SV; Torti, FM; Whitman, SP; Brechbiel, MW; Park, G; Planalp, RP. Blood. 1998;92:1384–1389. [PubMed]
7.
Turner, J; Koumenis, C; Kute, TE; Planalp, RP; Brechbiel, MW; Beardsley, D; Cody, B; Brown, KD; Torti, FM; Torti, SV. Blood. 2005;106:3191–3199. [PubMed]
8.
Buss, JL; Greene, BT; Turner, J; Torti, FM; Torti, SV. Curr Top Med Chem. 2004;4:1623–1635. [PubMed]
9.
Childers, M; Su, F; Przyborowska, AM; Biswokarma, B; Park, G; Broker, GA; Alexander, JS; Brechbiel, MW; Ruhlandt-Senge, K; Torti, SV; Torti, FM; Planalp, RP. Eur J Inorg Chem. 2005:3971–3982.
10.
Torti, SV; Ma, R; Venditto, VJ; Torti, FM; Planalp, RP; Brechbiel, MW. Bioorg Med Chem. 2005;13:5961–5967. [PubMed]
11.
Park, G; Lu, F; Ye, N; Brechbiel, M; Torti, S; Torti, F; Planalp, R. JBIC. J Biol Inorg Chem. 1998;3:449–457.
12.
Symons, MCR. Free Radicals and Iron: Chemistry, Biology, and Medicine. Oxford University Press; Oxford: 1998.
13.
Keene, FR. Coord Chem Rev. 1999;187:121–149.
14.
Planalp, RP; Przyborowska, AM; Park, G; Ye, N; Lu, FH; Rogers, RD; Broker, GA; Torti, SV; Brechbiel, MW. Biochem Soc Trans. 2002;30:758–762. [PubMed]
15.
Ma, D; Lu, F; Overstreet, T; Milenic, DE; Brechbiel, MW. Nucl Med Biol. 2002;29:91–105. [PubMed]
16.
Toftlund, H; Yde-Andersen, S. Acta Chem Scand, Series A. 1981;35:575–585.
17.
Hancock, RD; McDougall, GJ. J Chem Soc, Dalton Trans. 1977:67–70.
18.
J.H. Cho, R.P. Planalp, unpublished.
19.
Goto, M; Koga, N; Ohse, Y; Kurosaki, H; Komatsu, T; Kuroda, Y. J Chem Soc, Chem Commun. 1994:2015–2016.
20.
Holanda, MID; Krumholz, P; Chum, HL. Inorg Chem. 1976;15:890–893.
21.
Toma, HE; Stadler, E. Inorg Chim Acta. 1986;119:49–53.
22.
Ugalde-Saldivar, VM; Sosa-Torres, ME; Gonzalez, I. Eur J Inorg Chem. 2003:978–987.
23.
Bernhard, P; Bull, DJ; Buergi, HB; Osvath, P; Raselli, A; Sargeson, AM. Inorg Chem. 1997;36:2804–2815. [PubMed]
24.
Gomez, J; Garcia-Herbosa, G; Cuevas, JV; Arnaiz, A; Carbayo, A; Munoz, A; Falvello, L; Fanwick, PE. Inorg Chem. 2006;45:2483–2493. [PubMed]
25.
Keene, F; Ridd, M; Snow, M. J Am Chem Soc. 1983;105:7075–7081.
26.
Liu, S; Lee, S; Wang, S; Yeh, A; Gau, HM; Shao, MY. Inorg Chem. 2001;40:6139–6143. [PubMed]
27.
Ridd, M; Keene, F. J Am Chem Soc. 1981;103:5733–5740.
28.
Graf, E; Mahoney, J; Bryant, R; Eaton, J. J Biol Chem. 1984;259:3620–3624. [PubMed]
29.
Bernal, I; Jensen, IM; Jensen, KB; Mckenzie, CJ; Toftlund, H; Tuchagues, JP. J Chem Soc, Dalton Trans. 1995:3667–3675.
30.
Butcher, RJ; Addison, AW. Inorg Chim Acta. 1989;158:211–215.
31.
Christiansen, L; Hendrickson, DN; Toftlund, H; Wilson, SR; Xie, CL. Inorg Chem. 1986;25:2813–2818.
32.
Greenaway, AM; Sinn, E. J Am Chem Soc. 1978;100:8080.
33.
Alcock, NW; Zhang, D; Busch, DH. Acta Crystallographica, Section C: Crystal Structure Communications. 1999;C55:886–889.
34.
Mosmann, T. J Immunol Methods. 1983;65:55–63. [PubMed]